Overview

A Clinical Trial of Lurasidone in Treatment of Schizophrenia

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, double-dummy, parallel- controlled, adjustable dose, non-inferiority and multicentre study designed to evaluate the efficacy and safety of lurasidone on schizophrenia for 6 weeks treatment, and to compare with risperidone.
Phase:
Phase 3
Details
Lead Sponsor:
Sumitomo Pharmaceutical (Suzhou) Co., Ltd.
Treatments:
Lurasidone Hydrochloride
Risperidone